Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Buparlisib in Renal Impairment
NCT02048787Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of buparlisib in solid tumor (3 arms), sponsored by Novartis. Primary endpoints: Plasma pharmacokinetic parameter Cmax at 240 hours, Plasma pharmacokinetic parameter AUCinf at 240 hours and 3 more. Started Mar 2014; status: completed.
02
Drugs
buparlisib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02048787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048787.